Vascepa Gains European Filing Nod
No Rush In Search For Marketing Partner
Executive Summary
On the cusp of US approval, Amarin must wait until late 2020 for EMA judgement
You may also be interested in...
AZ Halts Epanova Study As High Placebo Effect Kills Acasti’s Omega-3 TRILOGY-1 Trial
Acasti’s omega-3 candidate drug CaPre missed the primary endpoint in TRILOGY-1 due to an unexplained high placebo effect, as AstraZeneca said its STRENGTH study was unlikely to show a treatment benefit.
Orchard’s Gene Therapy Under Fast-Track Review At EMA
A handful of new products are under review at the European Medicines Agency. Orchard Therapeutics' gene therapy application will be fast-tracked; Roche's filing for its new flu treatment will not.
Precision Keeps Faith In Duchenne Gene-Editing After Lilly’s Exit
The company has pledged to continue developing its Duchenne in vivo gene editing therapy without Lilly, but will remain focused on its lead program in hepatitis B.